

FORM PTO-1390 (Modified)  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

**RLL-159US**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)

**10/009,230**

INTERNATIONAL APPLICATION NO.

**PCT/IB00/00708**

INTERNATIONAL FILING DATE

**May 25, 2000**

PRIORITY DATE CLAIMED

**May 25, 1999**

TITLE OF INVENTION

**AMORPHOUS FORM OF FEXOFENADINE HYDROCHLORIDE**

APPLICANT(S) FOR DO/EO/US

**KUMAR et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

|  |   |   |
|--|---|---|
| U.S. APPLICATION NO. <b>10/009,230</b> (KNOWN, SEE 37 CFR 1.5) | INTERNATIONAL APPLICATION NO. <b>PCT/IB00/00763</b> | ATTORNEY'S DOCKET NUMBER <b>RLL-159US</b> |
|--|---|---|

|  |                     |                     |                  |                                  |           |
|--|---------------------|---------------------|------------------|----------------------------------|-----------|
| 24. The following fees are submitted:  |                     |                     |                  | <b>CALCULATIONS PTO USE ONLY</b> |           |
| <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b>   |                     |                     |                  |                                  |           |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . . . |                     |                     | <b>\$1040.00</b> |                                  |           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . .   |                     |                     | <b>\$890.00</b>  |                                  |           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . .  |                     |                     | <b>\$740.00</b>  |                                  |           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . .   |                     |                     | <b>\$710.00</b>  |                                  |           |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . .   |                     |                     | <b>\$100.00</b>  |                                  |           |
| <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>  |                     |                     |                  | <b>\$0.00</b>                    |           |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).                      |                     |                     |                  | <b>\$130.00</b>                  |           |
| <b>CLAIMS</b>  | <b>NUMBER FILED</b> | <b>NUMBER EXTRA</b> | <b>RATE</b>      |                                  |           |
| Total claims   | - 20 =              | 0                   | x \$18.00        | <b>\$0.00</b>                    |           |
| Independent claims   | - 3 =               | 0                   | x \$84.00        | <b>\$0.00</b>                    |           |
| Multiple Dependent Claims (check if applicable). <input type="checkbox"/>  |                     |                     |                  | <b>\$0.00</b>                    |           |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>   |                     |                     |                  | <b>\$130.00</b>                  |           |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.  |                     |                     |                  | <b>\$0.00</b>                    |           |
| <b>SUBTOTAL =</b>  |                     |                     |                  | <b>\$130.00</b>                  |           |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).                            |                     |                     |                  | <b>\$0.00</b>                    |           |
| <b>TOTAL NATIONAL FEE =</b>  |                     |                     |                  | <b>\$130.00</b>                  |           |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input checked="" type="checkbox"/>                        |                     |                     |                  | <b>\$40.00</b>                   |           |
| <b>TOTAL FEES ENCLOSED =</b>   |                     |                     |                  | <b>\$170.00</b>                  |           |
|  |                     |                     |                  | <b>Amount to be: refunded</b>    | <b>\$</b> |
|  |                     |                     |                  | <b>charged</b>                   | <b>\$</b> |

05/24/2002 GFREY1 00000118 500912 10009230  
01 F0:154 130.00 CH

- a. ☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-0912 in the amount of \$170.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0912. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jayadeep R. Deshmukh, Esq.  
Reg. No. 34, 507  
Ranbaxy Laboratories Limited  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Telephone: (609) 720-5608  
Facsimile: (609) 514-9779

  
SIGNATURE

Jayadeep R. Deshmukh

NAME

34, 507

REGISTRATION NUMBER

3 May 2002

DATE